* Histogen Inc HSTO.OQ HSTO.O is expected to show a fall
in
quarterly revenue when it reports results on May 12.
* Refinitiv's mean analyst estimate for Histogen Inc is for
a
loss of 7 cents per share. For the same quarter last year, the
company reported a loss of 14 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Histogen
Inc is
$2.25, above its last closing price of $0.17.
This summary was machine generated May 10 at 22:55 GMT. All
figures in US dollars unless otherwise stated